Immunotherapy with standardized extract of Dermataphagoides pteronyssinus in bronchial asthma: A dose-titration study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 2, 1997, Pages 168-178

  Olaguibel, J M ^a,c   Tabar, A I ^a   Garcia Figueroa B E ^a   Cortes C ^b  

^a HOSPITAL DE NAVARRA   (Spain)

^b Celltech Pharma España   (Spain)

^c Seccion de Alergologia   (Spain)

Author keywords

Bronchial asthma; Dose; House dust mite; Immunotherapy

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CROMOGLYCATE DISODIUM; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; SKIN TEST;

EID: 0030933308     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb00971.x     Document Type: Article

References (50)

1. Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol 1994;94:1-11.
2. Dreborg S, Mosbech H, Weeke B. Immunotherapy and bronchial asthma. In: Kay AB, editor. Clinical immunology and allergy. The allergic basis of asthma. London: Baillière Tindall, 1988.
3. Immunotherapy Subcommittee, EAACI. Immunotherapy. Position paper. Allergy 1988;43 Suppl 6.
4. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987;79:660-7.
5. Committee on Safety of Medicines. Desensitizing vaccines. BMJ 1986;293:948-52.
6. Bousquet J, Michel FB. Specific immunotherapy, past, present and future. Allergologie 1989;12:193-7.
7. Norman PS. Immunotherapy. In: Melillo G, Norman PS, Marone E, editors. Respiratory allergy. Toronto: BC Decker, 1990:3-15.
8. Bousquet J, Maasch HJ, Martinot B, et al. Double-blind, placebo-controlled, immunotherapy with mixed grass-pollen allergoid. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:439-46.
9. Turkeltaub PC, Rastogi SC, Baer H, et al. A standardized quantitative skin-test assay of allergen potency and stability studies on the allergen dose response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol 1982;70:343-52.
10. van Metre T Jr, Adkinson NF Jr. Immunotherapy for aeroallergen disease. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, editors. Allergy, principles and practice. Vol. II. St Louis, MO: CV Mosby, 1988:1327-44.
11. Platts-Mills TAE, Thomas WR, Aalberse RC, Vervloet D, Chapman MD. Dust mite allergens and asthma: report of a second international workshop. J Allergy Clin Immunol 1992;89:1046-60.
12. Turkeltaub PC. The importance of allergen dose on the safety and efficacy of immunotherapy of ragweed hay fever with standardized short ragweed extracts [Abstract]. J Allergy Clin Immunol 1986;77(part 2):211.
13. Basomba A. The importance of allergen dosage and treatment schedules in immunotherapy. XII International Congress of Allergology and Clinical Immunology, Washington, DC, 1985.
14. Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute, National Asthma Education Program, Expert Panel Report. J Allergy Clin Immunol 1991;88:425-534.
15. Brighton WD, Topping MD, Henocq E. Activity units for allergen extracts. Clin Allergy 1979;9:591-6.
16. Lombardero M, Gonzalez C, Duffort O, et al. Evaluación de la actividad biológica total y composición alergénica de los extrados alergénicos. Allergol Immunopathol (Madr) 1986; 14:189.
17. Ventas P, Lombardero M, Duffort O, Carreira J. Cuantificación de los alergenos Der p I y Der f I de los ácaros y Fel d I de gato mediante un ELISA en fase sólida. Rev Esp Alergol Inmunol Clin 1990;5:71-5.
18. Aas K. Heterogeneity of bronchial asthma. Allergy 1981; 36:3-14.
19. Finney DJ. Statistical methods in biological assay. 3th ed. London: Charles Griffin, 1978:69-104.
20. Dreborg S. Immunotherapy today and future demands on clinical investigations. Second Nordic Research Symposium Regarding Immunological and Pharmacological Mechanisms in Allergy/Nonallergy. University of Copenhagen, 1984:38-40.
21. Dreborg S. Skin tests used in type I allergy testing. Allergy 1989;44 Suppl 10:40-8.
22. Möller CH, Björkstén B, Nilsson G, Dreborg S. The precision of the conjunctival provocation test. Allergy 1984;39:37-41.
23. Sanchez-Madrid F, Morago G, Corbi A, Carreira J. Monoclonal antibodies to three distinct epitopes on human IgE: their use for determination of allergen-specific IgE. J Immunol Methods 1984;73:367-78.
24. Jimeno L, Carreira J, Lombardero M. Obtention of monoclonal antibodies against human IgG4 using two different immunization strategies: development of a biotin-based ELISA for Der p I quantitation. Int Arch Allergy Appl Immunol 1990;92:175-82.
25. Moscoso J, Jimeno L, Obispo T, Carreira J. Monoclonal antibodies against human IgE. Identification of an epitope sharing properties with the high affinity receptor binding site. Mol Immunol 1991;55:134-46.
26. Morago G, Carreira J, Corbi A, Sánchez Madrid F. Preparación de anticuerpos monoclonales frente a la IgG e IgE humanas y su utilización como reactivos en el diagnóstico de enfermedades alérgicas. Inmunología 1985;4:111-18.
27. Jimeno L, Serrano C, Moscoso J, Carreira J. An ELISA for the quantification of allergen specific IgG4 antibodies. Int Arch Allergy Appl Immunol 1992;94:120-75.
28. Mosbech H, Lind P. Collection of house dust for analysis of mite allergens. Allergy 1986;41:373-8.
29. Barber D, Chamorro MJ, Carpizo JA, et al. Valoración de la presión alergénica ambiental. Interés de esta determinación en la prevención, diagnóstico y tratamiento de las enfermedades alérgicas. Rev Esp Alergol Inmunol Clin 1990;5:125-32.
30. Tabar AI, García BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:450-3.
31. Mosbech H, Dirksen A, Dreborg S, et al. Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. IV. Occurrence and prediction of side effects. Allergy 1990;45:142-50.
32. D'Souza MF, Pepys J, Wells ID, et al. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clin Allergy 1973;3:177-93.
33. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990; 85:473-9.
34. Wahn U, Schweter C, Lind P, Løwenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988;82:360-70.
35. Mosbech H, Dreborg S, Frølund L, et al. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extracts. I. Clinical effect evaluated by diary cards and a retrospective assessment. Allergy 1989;44:487-98.
36. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin Allergy 1988;18:501-8.
37. Juniper EF, O'Connor J, Roberts RS, Evans S, Hargreave FE, Dolovich J. Polyethylene glycol-modified ragweed extract: comparison of two treatment regimens. J Allergy Clin Immunol 1986;78:851-6.
38. Mailing H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41:507-19.
39. Platts-Mills TAE, Chapman MD. Dust mites: immunology, allergic disease, and environmental control. J Allergy Clin Immunol 1987;80:755-75.
40. Dreborg S, Mosbech H, Weeke B. Immunotherapy and bronchial asthma. In: Kay AB, editor. Clinical immunology and allergy. The allergic basis of asthma. London: Baillière Tindall, 1988.
41. Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991;21 Suppl 1:206-10.
42. Mosbech H, Djurup R, Dreborg S, et al. Hyposensitization in asthmatics with mPEG modified and unmodified house dust mite extracts. III. Effect on mite-specific immunological parameters and correlation to changes in mitesensitivity and symptoms. Allergy 1990;45:130-41.
43. Einarsson R, Dreborg S, Hammarström L, et al. Monitoring of mite Dermatophagoides farinae allergen. Specific IgG and IgG subclass distribution in patients on immunotherapy. Allergy 1992;47:76-82.
44. Nakagawa T. IgG subclass changes in response to desensitisation. Monogr Allergy 1986;19:253-61.
45. Aalberse RC, Gaag R, Leuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983;130:722-6.
46. Devey ME, Wilson DV, Wheeler AW. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever during hyposensitization. Clin Allergy 1976;6:227-36.
47. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76: 734-44.
48. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91: 709-22.
49. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332:868-75.
50. McHugh SM, Ewan PW. A clinical index: a new method to assess efficacy of allergen immunotherapy. Allergy 1992; 47:115-20.